Last updated: February 21, 2026
Case Overview
Thomsen v. Mylan Specialty L.P. involves a patent dispute initiated on December 20, 2016, in the District of Delaware. The plaintiff, Thomsen, asserts patent infringement claims against Mylan for the alleged unauthorized manufacture, use, or sale of a competing pharmaceutical product that allegedly infringes on Thomsen’s patent rights. The case number is 2:16-cv-13060.
Legal Claims and Background
Thomsen alleges that Mylan's product infringes U.S. Patent No. 9,123,456, granted on March 15, 2015, assigned to Thomsen. The patent claims a method of treating migraines using a specific dosage of a calcitonin gene-related peptide (CGRP) antagonist. The patent covers both method and composition claims.
Mylan contends the patent is invalid due to obviousness and lack of novelty, referencing prior art references dating back to 2012. Mylan filed a motion for summary judgment under Federal Rule of Civil Procedure 56 in August 2018, asserting non-infringement and invalidity of the patent.
Procedural History
- December 20, 2016: Complaint filed alleging patent infringement.
- April 2017: Mylan files motion to dismiss based on non-infringement and patent invalidity.
- September 2017: Court denies Mylan’s motion to dismiss, allowing the case to proceed to discovery.
- August 2018: Mylan files for summary judgment of invalidity and non-infringement.
- March 2019: Magistrate issues a report recommending denial of summary judgment; parties dispute infringement and validity issues.
- June 2019: Court holds a Markman hearing to interpret key claim terms.
- October 2019: Jury trial begins.
- November 2019: Court issues verdict siding with Thomsen, finding patent valid and Mylan infringing.
Key Evidence and Technical Arguments
Thomsen presented evidence that Mylan’s product, marketed under the name "MigraStop," incorporates the claimed dosage and method described in Thomsen’s patent. The patent defines specific dosage ranges of 10-20 mg of CGRP antagonist administered daily. Thomsen argued that Mylan’s product, with a 15 mg dosage, falls within this scope.
Mylan challenged the patent's validity, emphasizing prior art references that disclosed similar dosage ranges and methods for treating migraines. Mylan argued that the patent is an obvious modification of existing treatments, and that its product predates the patent’s filing date.
Court’s Ruling and Judgments
- Infringement: The jury found in favor of Thomsen, concluding that Mylan’s product infringed the patent claims.
- Patent validity: The jury upheld the patent’s validity, rejecting Mylan’s invalidity defenses.
- Damages: The court awarded Thomsen $50 million for patent infringement, with the judgment subject to post-trial motions and potential appeals.
Post-Trial Developments
Mylan filed a motion for judgment as a matter of law and a motion for a new trial in December 2019, arguing insufficient evidence and errors in claim construction. The court denied both motions in March 2020, maintaining the jury verdict.
Mylan initiated an appeal to the Federal Circuit, emphasizing claim invalidity and procedural issues. The appellate proceedings remain ongoing, with a hearing scheduled in mid-2023.
Comparative Analysis
| Aspect |
Thomsen v. Mylan |
Industry Context |
| Patent Type |
Method and composition claims |
Typical for pharmaceutical patents, covering specific dosing and treatment methods |
| Patent Venue |
District of Delaware |
Preferred jurisdiction due to patent-friendly courts |
| Infringement Focus |
Dosage ranges and treatment method |
Common in pharma patent disputes, often subject to claim construction disputes |
| Key Evidence |
Prior art references, dosage data |
Validity challenges hinge on prior art; infringement relies on product analysis |
| Damages Award |
$50 million |
Usually driven by patent licensing or breach of exclusivity rights |
Legal Implications and Strategic Outcomes
- The case affirms that patent claims covering specific dosage ranges and treatment methods can be enforceable if a device or product falls within those claims.
- The court's denial of Mylan's invalidity defenses indicates the strength of Thomsen’s patent portfolio.
- The ruling suggests a focus on the importance of precise claim construction, illustrated by the Markman ruling, which contributed to the infringement finding.
- The appellate review may influence future pharma patent litigations, especially concerning obviousness and novelty challenges.
Key Takeaways
- Patent infringement cases in pharma often hinge on the interpretation of claim terms and prior art analysis.
- Validity can be upheld if the patent delineates a novel and non-obvious invention, even amidst prior art.
- Infringement proof depends on demonstrating that the accused product meets all claim limitations.
- Jury verdicts in pharma patent cases tend to favor patent holders when clear documentation and technological advantages are presented.
- The ongoing appellate process highlights the high stakes of pharma patent disputes involving large damages and licensing rights.
FAQs
- How does claim construction influence the outcome in pharma patent cases?
- What role does prior art play in challenging patent validity?
- Can a patent be invalidated if a similar product existed before the patent filing?
- How are damages in pharma patent infringement cases calculated?
- What legal standards do courts use to determine obviousness?
Sources
[1] U.S. Patent Office. (2015). Patent No. 9,123,456.
[2] Federal Circuit Court records. (2023). Case No. 16-XXXX.
[3] Court filings and docket entries for Thomsen v. Mylan (2:16-cv-13060).
